GILD - ギリアド・サイエンシズ （Gilead Sciences Inc.）

Stocks that traded heavily or had substantial price changes Wednesday: Alphabet, Brinker International rise; PayPal, Gilead fall

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC.

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus LogicBio Phase 1/2 Study Of Genome Editing Therapy In Methylmalonic Acidemia Placed On Clinical Hold LogicBio Therapeutics, Inc. (NASDAQ: LOGC ) announced the U.S. Food and Drug Administration has notified the company that its Phase 1/2 SUNRISE clinical trial of LB-001 in pediatric patients with methylmalonic acidemia has been placed on clinical hold. LB-001 is LogicBio''s investigational, single-administration, adeno-associated virus genome editing therapy. The company noted as reported earlier, the third patient dosed in the SUNRISE trial, who is in the younger age group of 6 months to 2 years old, experienced a drug-related serious adverse event, which was categorized as a case of thrombotic microangiopathy. The stock was sliding 16% to $1.26 in premarket trading. Click here to access Benzinga''s FDA Calendar Atea Announces Publication Of Positive Data On Investigational COVID-19 Treatment Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) announced the publication in the peer-reviewed journal "Nature Communications" new data demonstrating bemnifosbuvir''s unique mechanism of action that provides the potential to create a high barrier to resistance with broad antiviral activity across SARS-CoV-2 variants of concern.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have been given an average rating of “Buy” by the twenty-one ratings firms that are covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12-month price target among […]

Shoker Investment Counsel Inc. boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 12,837 shares of the biopharmaceutical companys stock after buying an additional 1,415 shares during the period. Shoker Investment Counsel Inc.s holdings []

Howland Capital Management LLC lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,536 shares of the biopharmaceutical companys stock after selling 1,669 shares during the period. Howland Capital []

Plimoth Trust Co. LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,505 shares of the biopharmaceutical companys stock after selling 747 shares during the period. Plimoth Trust Co. LLCs holdings []

Trial to evaluate antigen suppression combined with immunomodulation as a functional cure regimen for chronic HBV SAN FRANCISCO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ: VIR ) today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating novel therapeutic combinations for the treatment of chronic hepatitis B virus (HBV) infection. The multi-arm trial, which is being conducted in collaboration with Gilead Sciences, Inc., is assessing various combinations of VIR-2218, Vir''s investigational small interfering ribonucleic acid (siRNA) that mediates RNA interference (RNAi); selgantolimod (GS-9688), Gilead Sciences'' investigational TLR-8 agonist; and nivolumab, an approved PD-1 inhibitor, in both nucleos(t)ide (NUC)-suppressed patients and viremic patients. Patients with HBV treatment experience also may receive tenofovir alafenamide fumarate (TAF). "For the majority of patients with chronic HBV, a functional cure will likely require a sustained reduction in hepatitis B surface antigen and restoration of the immune response," said Carey Hwang, MD, PhD, senior vice president, clinical research, head of chronic infection for Vir Biotechnology. "We believe the combination of VIR-2218 and two immunomodulatory agents has the potential to improve the HBV-specific immune response and possibly achieve a functional cure.